TERT promoter mutations in thyroid cancer: growing evidence for a predictor of poor outcome

Jianliang Man, Norman Nicolson, Courtney Gibson, Tobias Carling


In the paper “TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma” published recently this year in The European Journal of Cancer, authors Bournaud et al. present a novel and interesting study investigating the relationship between telomerase reverse transcriptase (TERT) promoter mutations and clinical outcomes in intermediate and high-risk differentiated and poorly-differentiated thyroid cancers (1).